Disinfection Edge BLUEWAVE's patented vacuum-infusion disinfection system provides high-level, water-free sanitization with 99.9999% effectiveness against MRSA and other microbes, presenting a compelling value proposition for healthcare facilities seeking rapid, cost-effective infection prevention.

Home-Device Care The capability to treat patients' devices at home suggests opportunities to partner with hospitals and payors to expand post-acute care programs, reduce readmissions, and lower infection-related costs through at-home disinfection solutions.

Cost Reduction Health systems and providers may be interested in BLUEWAVE’s potential to lower infections and associated costs, creating a strong case for pilots with budget-conscious buyers aiming to optimize total cost of care.

Tech Stack Leverage With a cloud-based tech stack and monitoring capabilities, there is potential to offer data-driven usage analytics, remote support, and integration with healthcare IT systems to enhance adoption and demonstrate ROI.

Growth Potential Despite a small team, BLUEWAVE shows a significant funding position relative to revenue, indicating scalability opportunities through strategic partnerships, channel distributors, or government and vendor programs targeting infection control innovations.